Jason D. Lickliter

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme

Bryan W. Day, Brett W. Stringer, Fares Al‐Ejeh et al. · Cancer Cell · 2013 · 214 citations · Full text

Neuro-oncology, Glioma, Glioblastoma Multiforme +7

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

James R. Whittle, Jason D. Lickliter, Hui Gan et al. · Journal of Clinical Neuroscience · 2015 · 112 citations

Nanomedicine, Neuro-oncology, Drug Targeting +11

A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

Michael Grundman, Roger Morgan, Jason D. Lickliter et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2018 · 106 citations · Full text